HUTCHMED (China) Limited (FRA:H7T1)

Germany · Delayed Price · Currency is EUR

12.50

+0.10 (0.81%)

At close: Feb 20, 2026

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Oncology/Immunology - R&D	91.83M	364.45M	39.20M	-	-
Oncology/Immunology - R&D Growth	-74.80%	829.67%	-	-	-
Oncology/Immunology - Marketed Products	271.53M	164.17M	124.64M	-	-
Oncology/Immunology - Marketed Products Growth	65.40%	31.71%	-	-	-
Other Ventures	266.84M	309.38M	262.57M	236.52M	197.76M
Other Ventures Growth	-13.75%	17.83%	11.01%	19.60%	11.04%
Oncology/Immunology - R&D - PRC	-	-	-	43.18M	10.26M
Oncology/Immunology - R&D - PRC Growth	-	-	-	320.79%	-35.97%
Oncology/Immunology - Marketed Products - PRC	-	-	-	76.43M	19.95M
Oncology/Immunology - Marketed Products - PRC Growth	-	-	-	283.05%	85.33%
Total	630.20M	838.00M	426.41M	356.13M	227.98M
Total Growth	-24.80%	96.52%	19.73%	56.21%	11.27%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
People's Republic of China (PRC)	452.41M	484.90M	426.41M	-	-
People's Republic of China (PRC) Growth	-6.70%	13.72%	-	-	-
U.S. and Others	177.79M	353.10M	-	-	-
U.S. and Others Growth	-49.65%	-	-	-	-
Total	630.20M	838.00M	426.41M	-	-
Total Growth	-24.80%	96.52%	-	-	-

Source: S&P Global Market Intelligence.